Endo International (ENDP): Vasopressin Headlines Likely Worse than Reality - Citi

Endo International (ENDP) Reports Lift of Temporary Stay of FDA Litigation Following Launch of Bulk-Compounded Vasopressin Product by Section 503B Outsourcing Facility

Endo International plc (NASDAQ: ENDP) today announced that it is lifting a temporary stay of its litigation against the U.S. Food and Drug Administration (FDA). The litigation, filed in the U.S. District Court for the District of Columbia in October 2017 by the Company's subsidiaries, Par Sterile Products, LLC and Endo Par Innovation Company, LLC (collectively, "Endo"), seeks a declaration that FDA's "Interim Policy" on compounding using bulk drug substances under Section 503B of the Drug Quality and Security Act of 2013 (DQSA) amendments to the Federal Food, Drug, and Cosmetic Act (FDCA)... More

Endo International plc (ENDP) PT Raised to $17 at Mizuho Securities

Mizuho Securities analyst Irina Koffler raised the price target on Endo International plc (NASDAQ: ENDP) to $17.00 (from $10.00) while maintaining a Neutral rating.

Koffler comments "We still worry about the potential opioid liability and the competitive risks to Vasostrict and therefore reiterate our Neutral rating."

Endo International (ENDP) Weakness on Compounded Vasopressin Launch Bears Watching FDA Action - RBC

The downside in Endo International (NASDAQ: ENDP) (-2.7%) is related to news Athenex (NASDAQ: ATNX) announced that it had launched compounded Vasopressin injection (i.e. Vasostrict) in ready-to-use premix IV bags via Section 503B of the DQSA, RBC... More

Endo International plc (ENDP) PT Raised to $16 at BMO Capital

BMO Capital analyst Gary Nachman raised the price target on Endo International plc (NASDAQ: ENDP) to $16.00 (from $9.00) while maintaining a Market Perform rating.

RBC Capital Upgrades Endo International plc (ENDP) to Outperform on Cycle Up-Turn

(Updated - August 13, 2018 7:15 AM EDT)

(updated to add analyst comments)

RBC Capital analyst Randall Stanicky upgraded Endo International plc (NASDAQ: ENDP) from Sector Perform to Outperform with a price target of $26.00 (from $8.00).

Stanicky said the upgrade is in... More

Endo International plc (ENDP) PT Raised to $19 at Citi

Citi raised its price target on Endo International plc (NASDAQ: ENDP) to $19.00 (from $11.00) while maintaining a Buy rating.

Endo International plc (ENDP) PT Raised to $17 at Deutsche Bank

Deutsche Bank raised its price target on Endo International plc (NASDAQ: ENDP) to $17.00 (from $11.00) while maintaining a Buy rating.